Sustiva

Detectable HIV Levels Don’t Necessarily Increase the Risk of Cognitive Decline

Wednesday, August 26th, 2009

Having a viral load over 1,000 copies doesn’t necessarily increase the risk for cognitive decline—at least in people with high CD4 counts—according to a study published online August 18 in the Journal of Acquired Immune Deficiency Syndromes.
Recent studies have suggested that people living with HIV are experiencing health problems associated with aging—such as a cognitive [...]

Stepwise dosing schedule may ease neuropsychiatric side effects of efavirenz, trial indicates.

Tuesday, July 7th, 2009

 MedPage Today (7/6, Neale) reported, “A stepwise dosing schedule eases the neuropsychiatric side effects of the HIV drug efavirenz (Sustiva),” Spanish researchers found after conducting a trial that involved 114 patients. For 24 weeks, 60 participants “were randomized to the stepwise dosing schedule: daily doses of 200 mg for days one through six, 400 mg [...]